A Randomized Study to Compare a Monthly to a Daily Administration of Vitamin D₃ Supplementation

Sophie De Niet, Monte Coffiner, Stéphanie Da Silva, Bernard Jandrain, Jean-Claude Souberbielle, Etienne Cavalier, Sophie De Niet, Monte Coffiner, Stéphanie Da Silva, Bernard Jandrain, Jean-Claude Souberbielle, Etienne Cavalier

Abstract

We aimed to determine whether a cumulative dose of vitamin D₃ produces the same effects on the serum concentration of 25(OH)D₃ if it is given daily or monthly. This is a monocentric, two-armed, randomized, interventional, open, and parallel study conducted from November 2016 to March 2017 in Belgium. We randomized 60 subjects with vitamin D deficiency to receive 2000 IU vitamin D₃ daily or 50,000 IU monthly. The same cumulative dose of vitamin D₃ was given to each treatment group (150,000 IU). The 25(OH)D₃ serum concentrations from baseline to day 75 were 14.3 ± 3.7 to 27.8 ± 3.9 ng/mL in the monthly group and 14.1 ± 3.4 to 28.8 ± 5.4 ng/mL in the daily group. The mean change versus the baseline level was significantly different between the groups at day 2, 4, 7, and 14 and no longer different from day 25. One day after the intake of vitamin D₃, as expected, serum 25(OH)D₃ and 1,25(OH)₂D₃ increased significantly in the monthly group, whereas they did not change significantly in the daily group. The median time to reach the 20 ng/mL target concentration was significantly different in the two groups, in favor of the monthly regimen (1 day versus 14 days; p = 0.02). In conclusion, a monthly administration of 50,000 IU vitamin D₃ provides an effective tool for a rapid normalization of 25(OH)D₃ in deficient subjects. A daily administration of the same cumulative dose is similarly effective but takes two weeks longer to reach the desirable level of 20 ng/mL.

Keywords: FGF23; calcidiol; calcitriol; regimen; supplementation; vitamin D.

Conflict of interest statement

Sophie De Niet, Monte Coffiner, and Stéphanie Da Silva are employees of Laboratoires SMB SA. Etienne Cavalier is a consultant for Laboratoires SMB SA.

Figures

Figure 1
Figure 1
Study design.
Figure 2
Figure 2
Mean change of 25(OH)D3 serum concentrations over time. The error bars show the 95% confidence interval; * p < 0.05 between the treatment groups.
Figure 3
Figure 3
Mean change of 1,25(OH)2D3 serum concentrations over time. The error bars show the 95% confidence interval; * p < 0.05 between treatment groups.

References

    1. Holick M.F. Vitamin D deficiency. N. Engl. J. Med. 2007;357:266–281. doi: 10.1056/NEJMra070553.
    1. Zadshir A., Tareen N., Pan D., Norris K., Martins D. The prevalence of hypovitaminosis D among US adults: Data from the NHANES III. Ethn. Dis. 2005;15:97–101.
    1. Goodman W.G., London G., Amann K., Block G.A., Giachelli C., Hruska K.A., Ketteler M., Levin A., Massy Z., McCarron D.A., et al. Vascular calcification in chronic kidney disease. Am. J. Kidney Dis. 2004;43:572–579. doi: 10.1053/j.ajkd.2003.12.005.
    1. Gutierrez O.M., Mannstadt M., Isakova T., Rauh-Hain J.A., Tamez H., Shah A., Smith K., Lee H., Thadhani R., Jüppner H., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 2008;359:584–592. doi: 10.1056/NEJMoa0706130.
    1. Isakova T., Xie H.L., Yang W., Xie D., Anderson A.H., Scialla J., Wahl P., Gutiérrez O.M., Steigerwalt S., He J., et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011;305:2432–2439. doi: 10.1001/jama.2011.826.
    1. Wong R.G., Myrtle J.F., Tsai H.C., Norman A.W. The occurrence and biological activity of 1,25-dihydroxy-vitamin D3 in bone. J. Biol. Chem. 1972;247:5728–5735.
    1. Tsai H.C., Wong R.G., Norman A.W. Subcellular localization of 1,25-dihydroxy-vitamin D3 in intestinal mucosa and correlation with increased calcium transport. J. Biol. Chem. 1972;247:5511–5519.
    1. Myrtle J.F., Norman A.W. Vitamin D: A cholecalciferol metabolite highly active in promoting intestinal calcium transport. Science. 1971;171:79–82. doi: 10.1126/science.171.3966.79.
    1. Herrmann M., Farrell C.J.L., Pusceddu I., Fabregat-Cabello N., Cavalier E. Assessment of vitamin D status—A changing landscape. Clin. Chem. Lab. Med. 2017;55:3–26. doi: 10.1515/cclm-2016-0264.
    1. Pludowski P., Holick M.F., Grant W.B., Konstantynowicz J., Mascarenhas M.R., Haq A., Povoroznyuk V., Balatska N., Barbosa A.P., Karonova T., et al. Vitamin D supplementation guidelines. J. Steroid Biochem. Mol. Biol. 2018;175:125–135. doi: 10.1016/j.jsbmb.2017.01.021.
    1. Holick M.F., Binkley N.C., Bischoff-Ferrari H.A., Gordon C.M., Hanley D.A., Heaney R.P., Murad M.H., Weaver C.M. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J. Clin. Endocrinol. Metab. 2012;97:1153–1158. doi: 10.1210/jc.2011-2601.
    1. Rosen C.J., Abrams S.A., Aloia J.F., Brannon P.M., Clinton S.K., Durazo-Arvizu R.A., Gallagher J.C., Gallo R.L., Jones G., Kovacs C.S., et al. IOM committee members respond to Endocrine Society vitamin D guideline. J. Clin. Endocrinol. Metab. 2012;97:1146–1152. doi: 10.1210/jc.2011-2218.
    1. Rizzoli R., Boonen S., Brandi M.L., Bruyère O., Cooper C., Kanis J.A., Kaufman J.M., Ringe J.D., Weryha G., Reginster J.Y. Vitamin D supplementation in elderly or postmenopausal women: A 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) Curr. Med. Res. Opin. 2013;29:305–313. doi: 10.1185/03007995.2013.766162.
    1. Bischoff-Ferrari H.A., Willett W.C., Orav E.J., Lips P., Meunier P.J., Lyons R.A., Flicker L., Wark J., Jackson R.D., Cauley J.A., et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N. Engl. J. Med. 2012;367:40–49. doi: 10.1056/NEJMoa1109617.
    1. Bouillon R. Comparative analysis of nutritional guidelines for vitamin D. Nat. Rev. Endocrinol. 2017;13:466–479. doi: 10.1038/nrendo.2017.31.
    1. Cashman K.D., Kiely M. Recommended dietary intakes for vitamin D: Where do they come from, what do they achieve and how can we meet them? J. Hum Nutr. Diet. 2014;27:434–442. doi: 10.1111/jhn.12226.
    1. Silverman S., Gold D.T. Compliance and persistence with osteoporosis medications: A critical review of the literature. Rev. Endocr. Metab. Disord. 2010;11:275–280. doi: 10.1007/s11154-010-9138-0.
    1. Tang B.M., Eslick G.D., Nowson C., Smith C., Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: A meta-analysis. Lancet. 2007;370:657–666. doi: 10.1016/S0140-6736(07)61342-7.
    1. Di Mauro G., Saggese G. Italian Consensus on vitamin D in Infants and Children. Prev. Soc. Pediatr. 2015;3:154–188.
    1. Rabenda V., Mertens R., Fabri V.E., Vanoverloop J., Sumkay F., Vannecke C., Deswaef A., Verpooten G.A., Reginster J.Y. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos. Int. 2008;19:811–818. doi: 10.1007/s00198-007-0506-x.
    1. Rabenda V., Hiligsmann M., Reginster J.Y. Poor adherence to oral bisphosphonate treatment and its consequences: A review of the evidence. Expert. Opin. Pharmacother. 2009;10:2303–2315. doi: 10.1517/14656560903140533.
    1. Ish-Shalom S., Segal E., Salganik T., Raz B., Bromberg I.L., Vieth R. Comparison of daily, weekly, and monthly vitamin D3 in ethanol dosing protocols for two months in elderly hip fracture patients. J. Clin. Endocrinol. Metab. 2008;93:3430–3435. doi: 10.1210/jc.2008-0241.
    1. Takacs I., Toth B.E., Szekeres L., Szabo B., Bakos B., Lakatos P. Randomized clinical trial to comparing efficacy of daily, weekly and monthly administration of vitamin D3. Endocrine. 2016;55:60–65. doi: 10.1007/s12020-016-1137-9.
    1. Chel V., Wijnhoven H.A., Smit J.H., Ooms M., Lips P. Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents. Osteoporos. Int. 2008;19:663–671. doi: 10.1007/s00198-007-0465-2.
    1. Cavalier E., Lukas P., Crine Y., Peeters S., Carlisi A., Le Goff C., Gadisseur R., Delanaye P., Souberbielle J.C. Evaluation of automated immunoassays for 25(OH)-vitamin D determination in different critical populations before and after standardization of the assays. Clin. Chim. Acta. 2014;431:60–65. doi: 10.1016/j.cca.2014.01.026.
    1. Binkley N., Gemar D., Engelke J., Gangnon R., Ramamurthy R., Krueger D., Drezner M.K. Evaluation of ergocalciferol or cholecalciferol dosing 1600 IU daily or 50000 IU monthly in older adults. J. Clin. Endocrinol. Metab. 2011;96:981–988. doi: 10.1210/jc.2010-0015.
    1. Courbebaisse M., Thervet E., Souberbielle J.C., Zuber J., Eladari D., Martinez F., Mamzer-Bruneel M.F., Urena P., Legendre C., Friedlander G., et al. Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. Kidney Int. 2009;75:646–651. doi: 10.1038/ki.2008.549.
    1. Romagnoli E., Mascia M.L., Cipriani C., Fassino V., Mazzei F., D’erasmo E., Carnevale V., Scillitani A., Minisola S. Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J. Clin. Endocrinol. Metab. 2008;93:3015–3020. doi: 10.1210/jc.2008-0350.
    1. Bacon C.J., Gamble G.D., Horne A.M., Scott M.A., Reid I.R. High-dose oral vitamin D3 supplementation in the elderly. Osteoporos. Int. 2009;20:1407–1415. doi: 10.1007/s00198-008-0814-9.
    1. Cavalier E., Faché W., Souberbielle J.C. A randomised, double-blinded, placebo-controlled, parallel study of vitamin D3 supplementation with different schemes based on multiples of 25,000 IU doses. Int. J. Endocrinol. 2013;2013 doi: 10.1155/2013/327265.
    1. Sanders K.M., Stuart A.L., Williamson E.J., Simpson J.A., Kotowicz M.A., Young D., Nicholson G.C. Annual high-dose oral vitamin D and falls and fractures in older women: A randomized controlled trial. JAMA. 2010;30:1815–1822. doi: 10.1001/jama.2010.594.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner